Robin L. Jones, MD, MBBS, of The Royal Marsden/Institute of Cancer Research, discusses the first phase III study in angiosarcoma, which showed no difference in outcome between pazopanib vs pazopanib plus the novel monoclonal antibody TRC105 (Abstract 1667O).
Nicoletta Colombo, MD, of Istituto Europeo di Oncologia, discusses the efficacy of lenvatinib/pembrolizumab in metastatic endometrial cancer. The combination showed antitumor...
Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses study findings which showed that cabazitaxel improved radiographic progression-free survival as ...
Ghassan K. Abou-Alfa, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings showing improvement in progression-free survival among patients w...
Antonio González Martín, MD, PhD, of the Clínica Universidad de Navarra, discusses study findings showing niraparib therapy significantly improved progression-free survival i...
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses long-term outcomes from a phase II trial which showed that nivolumab/ipili...